If you or someone you love has been diagnosed with microscopic polyangiitis, you have likely already learned how frightening a diagnosis it can be. One week the symptoms are vague: fatigue, joint aches, a strange tingling in the feet, blood that shows up on a urine test you almost skipped. The next week you are in a nephrologist's office hearing words like "rapidly progressive glomerulonephritis," "alveolar hemorrhage," and "induction immunosuppression." MPA can move fast, and when it does, it threatens the kidneys and lungs in ways that demand urgent, expert medical care.

This page is written for people living with MPA, and for their families, who want to understand the disease at a deeper level and who are curious whether a whole-food like wildcrafted sea moss has any rational place alongside their treatment. The honest answer is nuanced. Sea moss is not a treatment for vasculitis and will never replace rituximab, cyclophosphamide, corticosteroids, plasma exchange, or the monitoring your specialists provide. But several of its components, especially the marine polysaccharide fucoidan, the trace mineral selenium, omega-3 precursors, and zinc, touch biological pathways that are central to the way MPA injures blood vessels. Understanding those pathways is genuinely useful, both for appreciating your own disease and for having a more informed conversation with your care team. That is what this page is for.

What Microscopic Polyangiitis Actually Is

Microscopic polyangiitis belongs to a family of diseases called the ANCA-associated vasculitides, or AAV. "Vasculitis" simply means inflammation of blood vessels. "ANCA" stands for anti-neutrophil cytoplasmic antibodies, the rogue autoantibodies that sit at the heart of how this disease works. In MPA specifically, the inflammation strikes the smallest blood vessels in the body: the capillaries, the venules (tiny veins), and the arterioles (tiny arteries). Because these microscopic vessels supply the filtering units of the kidney and the delicate gas-exchange surfaces of the lung, MPA tends to hit those two organs hardest.

The three classic ANCA-associated vasculitides are microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA, formerly called Wegener's), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss). They overlap, but each has its own fingerprint. What sets MPA apart is what it lacks. Unlike GPA, MPA does not form granulomas, the organized clumps of immune cells that give GPA its name, and MPA generally spares the upper airway, so the chronic sinusitis, nasal crusting, and saddle-nose deformity of GPA are not features of MPA. Unlike EGPA, MPA is not driven by eosinophils and is not associated with asthma or the high eosinophil counts that define EGPA. MPA, in short, is a "pure" small-vessel necrotizing vasculitis without granulomas, without upper-airway disease, and without eosinophilia.

The Pathophysiology: How Anti-MPO ANCA Injures Your Vessels

To understand where any nutrient could plausibly help, you have to understand the precise sequence of events that turns a quiet neutrophil into an agent of vascular destruction. This is one of the better-understood autoimmune mechanisms in medicine, and walking through it step by step makes the rationale for certain marine compounds far clearer.

Step 1: Cytokine priming

The chain of events begins with priming. In a healthy state, the enzyme myeloperoxidase stays locked inside the neutrophil, hidden from the immune system. But when the body is exposed to inflammatory signals, particularly the priming cytokines tumor necrosis factor alpha (TNF-alpha) and interleukin-18 (IL-18), the neutrophil becomes activated and begins to translocate, or externalize, myeloperoxidase to its outer surface. Often this priming is triggered by an infection, which is one reason MPA flares can follow illnesses. Now MPO, the very antigen the anti-MPO antibodies recognize, is exposed and accessible on the cell membrane.

Step 2: ANCA binding

With MPO now displayed on the neutrophil surface, circulating anti-MPO ANCA antibodies bind to it. This binding is the spark. It cross-links the MPO antigen and simultaneously engages Fc receptors on neighboring neutrophils, delivering a powerful activation signal directly into the cell.

Step 3: Neutrophil activation and the oxidative burst

Once fully activated by ANCA binding, the neutrophil unleashes what is called the oxidative burst, also known as the respiratory burst. The enzyme complex NADPH oxidase assembles and pumps out superoxide, which is rapidly converted to hydrogen peroxide. Myeloperoxidase then uses that hydrogen peroxide to manufacture hypochlorous acid (HOCl), the same chemical found in bleach, an extraordinarily potent oxidant. These reactive oxygen species are meant to kill microbes, but when released against the body's own vessel walls, they cause severe oxidative injury to the endothelium, the single-cell lining of blood vessels.

Step 4: NET release

Activated neutrophils also do something more dramatic: they extrude neutrophil extracellular traps, or NETs. A NET is a web of decondensed DNA studded with antimicrobial enzymes, including, critically, MPO itself. In healthy infection-fighting, NETs trap bacteria. In MPA, NET formation has gone haywire. The NETs deposit MPO directly onto and into the vessel wall, injure the endothelium, activate the complement system, and act as a self-perpetuating source of the very MPO antigen that started the cycle, feeding ongoing autoantibody production. Excessive, poorly cleared NETs are now considered a central driver of vascular injury in ANCA-associated vasculitis. This is a crucial concept, because it identifies NET formation as one of the most important therapeutic and nutritional targets in MPA.

Step 5: Endothelial injury and small-vessel necrosis

The combined assault of oxidants, NETs, and direct neutrophil degranulation damages and kills endothelial cells. The vessel wall becomes inflamed and undergoes fibrinoid necrosis, a form of tissue death. Because the affected vessels are so small (capillaries, venules, arterioles), the consequences depend entirely on which organ's microvasculature is involved. Two organs dominate the clinical picture.

How MPA Injures the Kidneys

The kidney is the organ most often and most seriously affected in MPA. The hallmark lesion is pauci-immune focal segmental necrotizing glomerulonephritis (FSNGN). Let us unpack that mouthful, because each word tells you something important.

• Glomerulonephritis means inflammation of the glomeruli, the millions of tiny filtering tufts of capillaries where blood is cleaned to make urine.
• Necrotizing means the inflammation is destroying tissue, killing segments of the glomerular capillary loops.
• Focal segmental means only some glomeruli are involved (focal), and within an affected glomerulus only part of it is damaged (segmental), at least early on.
• Pauci-immune is the defining feature. "Pauci" means few. When a pathologist examines a kidney biopsy under immunofluorescence (IF), they find few or no immune-complex deposits, unlike lupus nephritis or IgA nephropathy, which are full of deposits. In MPA, the damage is driven by the activated neutrophils themselves, not by trapped antibody complexes. This "pauci-immune" pattern is the signature of ANCA-associated glomerulonephritis.

Clinically, this glomerular destruction produces an active urinary sediment: microscopic or visible blood in the urine (hematuria), red blood cell casts (cylindrical molds of red cells that form in the kidney tubules and are a tell-tale sign of glomerular bleeding), and protein leaking into the urine (proteinuria). Because the necrotizing inflammation can advance over days to weeks, MPA is one of the classic causes of rapidly progressive glomerulonephritis (RPGN), in which kidney function can plummet toward acute kidney injury (AKI) and even dialysis-dependent failure in a frighteningly short time. This is why prompt diagnosis and treatment are not optional in MPA. Days matter.

How MPA Injures the Lungs

The second great danger of MPA is in the lungs. When the small vessels of the alveoli (the air sacs) become inflamed, the result is pulmonary capillaritis. The delicate barrier between the air sacs and the bloodstream breaks down, and blood floods into the alveoli. This is diffuse alveolar hemorrhage (DAH), and it is a true medical emergency.

The signs can be deceptively variable. Some people cough up blood (hemoptysis), but not everyone does, because the blood can pool in the lungs without being coughed up. Other clues include sudden shortness of breath, falling oxygen levels, new patchy shadows on a chest X-ray or CT scan, and an unexplained drop in hemoglobin (anemia) as blood is lost into the lungs. Because DAH can be rapidly fatal, any person with MPA who develops breathlessness, hemoptysis, or a dropping blood count needs immediate hospital evaluation.

Beyond the Kidneys and Lungs: The Other Faces of MPA

MPA is systemic, so its small-vessel inflammation can show up in many places:

• Peripheral nerves: One of the more characteristic features is mononeuritis multiplex, in which the blood supply to individual nerves is interrupted by vasculitis, causing patchy numbness, burning pain, or weakness, classically a foot drop or wrist drop. This peripheral neuropathy can be one of the earliest signs.
• Skin: Inflammation of small dermal vessels produces palpable purpura, raised purple-red spots, typically on the lower legs, that you can feel as well as see.
• Gastrointestinal tract: Mesenteric vasculitis can cause abdominal pain, bleeding, and, rarely, bowel ischemia.
• Constitutional symptoms: Fever, weight loss, night sweats, profound fatigue, and joint and muscle aches are extremely common and often precede organ-specific findings by weeks.

Laboratory markers usually show a brisk inflammatory response: the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are typically elevated, while, as noted, complement levels are usually normal. Disease activity is formally tracked using the Birmingham Vasculitis Activity Score (BVAS), a structured tool that tallies active features across organ systems. Importantly, ANCA antibody levels (titres) correlate only imperfectly with disease activity. ANCA can stay positive when the disease is quiet, and a rising titre is a warning sign worth watching but not a perfect predictor of relapse. This imperfect correlation is one reason monitoring relies on urinalysis, kidney function, and symptoms as much as on the antibody level itself.

MPA vs GPA vs EGPA: A Side-by-Side Comparison

Because the three ANCA-associated vasculitides are so often confused, this table lays out the distinguishing features at a glance.

Feature	MPA (Microscopic Polyangiitis)	GPA (Wegener's)	EGPA (Churg-Strauss)
Typical ANCA type	p-ANCA / anti-MPO (majority)	c-ANCA / anti-PR3 (majority)	p-ANCA / anti-MPO (~40%), often ANCA-negative
Granulomas	Absent	Present (defining feature)	Present (eosinophilic granulomas)
Upper airway / sinus disease	Generally absent	Prominent (sinusitis, nasal crusting, saddle nose)	Common (allergic rhinitis, nasal polyps)
Eosinophilia / asthma	Absent	Absent	Defining (asthma + high eosinophils)
Kidney involvement	Very common, often severe RPGN	Common	Less common, usually milder
Lung involvement	Alveolar hemorrhage (capillaritis)	Nodules, cavities, hemorrhage	Asthma, eosinophilic infiltrates
Relapse rate	Lower than GPA (especially anti-MPO)	Higher (especially anti-PR3)	Variable

How Sea Moss Components Map to MPA Biology

With the mechanism clear, we can now look honestly at each relevant nutrient in wildcrafted sea moss and ask: does it plausibly touch any step in the cascade described above? The answer, for several of them, is yes, but always with the caveat that most of this evidence is preclinical (cell and animal studies) rather than clinical trials in MPA patients. Sea moss is a nutritional foundation, not a drug.

Fucoidan: The Most Mechanistically Interesting Component

Fucoidan is a sulfated polysaccharide concentrated in marine seaweeds, and of all sea moss components it maps most directly onto MPA pathophysiology. Several of its documented activities line up with the steps of the ANCA cascade.

• NF-kB suppression in endothelial cells: The transcription factor NF-kB is the master switch for inflammatory gene expression. When ANCA-activated neutrophils and cytokines hit endothelial cells, NF-kB drives the production of adhesion molecules and chemokines that recruit more neutrophils, amplifying the attack. Fucoidan has repeatedly been shown in laboratory models to suppress NF-kB activation in endothelial cells, which would, in principle, blunt this ANCA-triggered endothelial activation loop.
• NET inhibition: This is arguably the most important point on the whole page. Because excessive NET formation is a central driver of vascular injury in MPA, any compound that restrains NETosis is mechanistically compelling. Fucoidan and related sulfated polysaccharides have shown the ability to interfere with neutrophil extracellular trap formation and to modulate NET-driven inflammation in experimental settings. In a disease defined partly by runaway NETs, that is a rationally interesting property, though far from a proven clinical benefit.
• IL-6 and TNF-alpha reduction: Since TNF-alpha is a key priming cytokine that externalizes MPO and sets up the whole cascade, lowering the inflammatory cytokine burden is meaningful. Fucoidan has demonstrated anti-inflammatory effects that include reducing IL-6 and TNF-alpha production, which would reduce the priming signals that prepare neutrophils for ANCA-triggered activation.
• Oxidative burst attenuation: Some studies suggest sulfated polysaccharides can dampen the neutrophil respiratory burst, reducing the output of superoxide and downstream HOCl that does so much endothelial damage.
• Complement alternative pathway modulation: Given that C5a amplification is now understood to be important in AAV, the documented ability of sulfated marine polysaccharides to modulate the alternative complement pathway is mechanistically relevant, the same general axis that the drug avacopan targets pharmacologically.
• Gut mucosal barrier support: Fucoidan and the prebiotic fibers in sea moss nourish the gut barrier. A leaky gut allows bacterial lipopolysaccharide (LPS) to translocate into the bloodstream, and LPS is a potent neutrophil-priming signal. By supporting mucosal integrity and reducing LPS translocation, fucoidan may indirectly reduce one source of the systemic priming that primes neutrophils for ANCA activation.

Selenium: Cofactor for the Antioxidant Defenses Under Siege

If the oxidative burst is one of the weapons MPA uses against your vessels, then the body's antioxidant enzymes are the shields, and many of those shields literally cannot function without selenium. This makes selenium status genuinely relevant to MPA biology.

• Glutathione peroxidases (GPx1/2) in the kidney: The selenium-dependent enzymes GPx1 and GPx2 neutralize hydrogen peroxide and lipid peroxides. In the renal tubular cells and glomerular cells bearing the brunt of vasculitic oxidative injury, robust GPx activity helps limit the damage. Without adequate selenium, these enzymes are crippled.
• Thioredoxin reductase (TrxR1) and the oxidative burst: TrxR1 is another selenoenzyme central to redox balance. By keeping cellular antioxidant systems charged, adequate selenium helps reduce the pool of hydrogen peroxide that myeloperoxidase would otherwise convert into bleach-like HOCl. In a sense, good selenium status reduces the raw material available for MPO-driven oxidant production.
• Selenoprotein P in lung tissue: Selenoprotein P transports selenium and provides antioxidant protection to tissues including the lung, the very organ at risk of capillaritis and alveolar hemorrhage in MPA.
• GPx4 and protection against ferroptosis: GPx4 is a unique selenoenzyme that prevents ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation. Renal tubular cells are particularly vulnerable to ferroptosis during injury, and GPx4, dependent on selenium, is the main brake on that process.
• Selenium and neutrophil MPO production: There is research interest in how selenium status influences neutrophil myeloperoxidase activity and the balance of the oxidative burst, another reason selenium sufficiency is plausibly relevant in an MPO-driven disease.
• Documented deficiency in AAV: Patients with active ANCA-associated vasculitis, and critically ill or chronically inflamed patients generally, often show low selenium status, precisely when their antioxidant defenses are most needed.

Omega-3 Fatty Acids (EPA/DHA): Resolution and Nerve Protection

The omega-3 fatty acids EPA and DHA are precursors to a remarkable family of molecules called specialized pro-resolving mediators, which do not merely suppress inflammation but actively orchestrate its resolution. Several of these are directly relevant to MPA.

• EPA-derived resolvins E1 and E2: These resolvins reduce neutrophil recruitment to inflamed tissue. Since neutrophils are the central effector cells in MPA, dampening their excessive infiltration into vessel walls is mechanistically attractive.
• Protectin D1 (neuroprotectin D1): This DHA-derived mediator is neuroprotective, which is especially relevant to the mononeuritis multiplex and peripheral neuropathy that MPA can cause. Protecting nerve tissue from ischemic and inflammatory injury is a plausible supportive angle for nerve-related symptoms.
• PGE2 and LTB4 suppression: Omega-3s shift the balance of eicosanoids away from pro-inflammatory prostaglandin E2 (PGE2) and leukotriene B4 (LTB4). LTB4 in particular is one of the most powerful neutrophil chemoattractants known, so reducing it can reduce the chemotactic pull that draws neutrophils into vessel walls.
• DHA in neuronal membranes: DHA is a structural fatty acid in nerve cell membranes, supporting nerve membrane integrity, again relevant to the neuropathy of MPA.
• Renal protection context: Omega-3s have been studied for anti-inflammatory effects in various kidney conditions, providing a general supportive backdrop for renal health, though not a vasculitis treatment.
• EPA and platelet function: EPA has mild antiplatelet effects. This is a double-edged consideration in MPA: helpful in many contexts but a reason for caution given the risk of pulmonary hemorrhage, which must be weighed with your physician.

Zinc: Tuning the Neutrophil and the T-Cell Balance

Zinc is a quietly essential mineral in immune regulation, and several of its roles connect to MPA biology, though with an important note of balance.

• Neutrophil oxidative burst: Zinc modulates the neutrophil respiratory burst, and in several models zinc chelation or sufficiency can attenuate excessive reactive oxygen species production. Adequate zinc status supports a more measured, less destructive neutrophil response.
• FOXP3+ regulatory T-cell induction: Zinc supports the induction of FOXP3-positive regulatory T-cells (Tregs), the immune system's peacekeepers. By favoring Tregs, zinc can help dampen the pathogenic Th17-skewed inflammation that contributes to autoimmune vasculitis.
• NET formation, a note of balance: The relationship between zinc and NETs is not one-directional. While adequate zinc status supports balanced neutrophil function, certain zinc ionophores can paradoxically induce NET formation in some experimental conditions. The lesson is balance rather than excess, dietary sufficiency rather than aggressive supplementation.
• MMP regulation in vessel remodeling: Zinc is a cofactor for matrix metalloproteinases (MMPs), enzymes involved in remodeling the vessel wall after injury. Proper zinc-dependent regulation matters for healthy tissue repair following vasculitic damage.
• Renal zinc transporters: Zinc homeostasis in the kidney is managed by transporters such as the ZIP (ZIP4) and ZnT families, and adequate zinc supports normal renal tubular cell function.

Iodine: The Thyroid Consideration

Sea moss naturally contains iodine, sometimes in substantial and variable amounts. For most people this is part of its nutritional value, supporting normal thyroid hormone production. But for anyone with MPA there are two reasons to pay attention. First, autoimmune thyroid disease can coexist with other autoimmune conditions, and excess iodine can aggravate an autoimmune thyroid. Second, some MPA patients take medications and have organ involvement that make any new variable worth discussing with their physician. The practical guidance is to keep iodine intake moderate and consistent, and to involve your provider, especially if you have any thyroid condition. Tolerability is generally good at sensible servings, but more is not better.

How MPA Is Diagnosed

Understanding the diagnostic workup helps you make sense of the many tests your team will order. Diagnosis weaves together clinical features, blood and urine markers, antibody testing, imaging, and, ideally, a tissue biopsy.

• Urinalysis with microscopy: Often the single most informative bedside test. It looks for hematuria (blood), red blood cell casts (a sign of glomerular bleeding), and proteinuria. An active urinary sediment is a red flag for glomerulonephritis.
• Complete blood count (CBC): May reveal anemia (from blood loss in alveolar hemorrhage or chronic inflammation) and clues to the inflammatory state.
• Serum creatinine and kidney function: Tracks the severity and trajectory of kidney involvement; a rising creatinine signals worsening function.
• ANCA testing: Performed by both immunofluorescence (IF), which gives the p-ANCA or c-ANCA pattern, and ELISA, which identifies the specific target (anti-MPO or anti-PR3). The combination is more reliable than either alone.
• Complement levels: Usually normal in MPA, which helps exclude immune-complex diseases like lupus.
• Chest imaging: A chest X-ray or, better, a CT scan can reveal the patchy infiltrates of alveolar hemorrhage.
• Renal biopsy, the gold standard: A kidney biopsy showing pauci-immune focal segmental necrotizing glomerulonephritis confirms the diagnosis and helps grade severity and likely reversibility, which guides treatment intensity.
• Bronchoscopy: When DAH is suspected, bronchoscopy with serial bronchoalveolar lavage (the fluid becomes progressively bloodier) confirms alveolar hemorrhage.

How MPA Is Treated

This section exists so you understand what real treatment looks like and why sea moss can never substitute for it. MPA treatment is divided into two phases: induction, to bring severe active disease under control quickly, and maintenance, to keep it in remission and prevent relapse.

Induction therapy

For severe, organ-threatening MPA, induction combines a potent immunosuppressant with high-dose corticosteroids.

• Rituximab: A monoclonal antibody that depletes B-cells, the cells that produce ANCA. The landmark RAVE and RITUXVAS trials established that rituximab is at least as effective as cyclophosphamide for inducing remission in ANCA-associated vasculitis, and it has become a preferred option for many patients, particularly those wishing to avoid cyclophosphamide's fertility and toxicity risks.
• Cyclophosphamide: A powerful older immunosuppressant, still used, especially in the most severe presentations, often given intravenously in pulses. It remains highly effective induction therapy.
• High-dose corticosteroids: Glucocorticoids (often starting with intravenous methylprednisolone pulses, then oral prednisone) rapidly suppress inflammation and are given alongside rituximab or cyclophosphamide.
• Plasma exchange (plasmapheresis): The PEXIVAS trial refined the role of plasma exchange. It is no longer used routinely for all severe AAV, but it retains a role in selected patients with severe renal involvement (very high creatinine or dialysis dependence) and is often considered in life-threatening alveolar hemorrhage, where removing circulating ANCA may help.
• Avacopan: Approved in 2021, avacopan is an oral inhibitor of the complement C5a receptor (C5aR). It targets the complement amplification pathway described earlier and allows a substantial reduction in corticosteroid exposure, a meaningful advance given the heavy burden of steroid side effects.

Maintenance therapy

Once remission is achieved, treatment shifts to gentler, longer-term immunosuppression to prevent relapse.

• Azathioprine or mycophenolate mofetil (MMF): Traditional oral maintenance agents that keep the immune system in check after cyclophosphamide induction.
• Maintenance rituximab: Many centers now use scheduled rituximab (for example, every six months) for maintenance, particularly in patients at high relapse risk, an approach supported by trials showing superior relapse prevention.

Renal Prognosis: What to Know

Kidney outcomes in MPA depend heavily on how quickly treatment begins and how much irreversible scarring has already occurred at diagnosis. The creatinine level at presentation, and the proportion of normal versus scarred glomeruli on biopsy, are among the strongest predictors of long-term kidney function. Some patients recover substantial kidney function with prompt treatment; others, particularly those who present late with advanced damage, progress to end-stage renal disease (ESRD) and require dialysis or, eventually, transplantation. The creatinine trajectory in the first weeks of treatment is watched closely. For patients who reach ESRD, dialysis considerations and timing are managed by the nephrology team, and immunosuppression strategy may shift once the kidneys are no longer salvageable but other organs still need protection. This is highly individualized, expert-driven care, and it underscores why early diagnosis is so consequential.

Diffuse Alveolar Hemorrhage: An Emergency

Relapse Monitoring and the Two MPA Subsets

Even after remission, MPA can relapse, so ongoing surveillance is part of life with the disease. Monitoring weaves together several threads:

• ANCA titres: A rising anti-MPO level can be a warning sign of impending relapse, but because ANCA correlates only imperfectly with activity, it is interpreted alongside other data rather than acted on in isolation.
• Urinalysis: The reappearance of blood, red cell casts, or new proteinuria is a sensitive early signal of renal relapse and is checked regularly.
• Symptoms and exam: Returning fatigue, fever, weight loss, new neuropathy, purpura, or respiratory symptoms prompt closer evaluation, often using the BVAS to quantify activity.

Where Sea Moss Honestly Fits: A Summary Table

Component	Relevant mechanism in MPA	Honest limit
Fucoidan	NF-kB suppression, NET inhibition, IL-6/TNF-alpha reduction, oxidative burst attenuation, complement modulation, gut barrier support	Preclinical evidence; not an immunosuppressant; mild antiplatelet effect (hemorrhage caution)
Selenium (selenomethionine)	Cofactor for GPx1/2, TrxR1, GPx4 (anti-ferroptosis) and selenoprotein P protecting renal and lung tissue from oxidant injury	Narrow safe range; baseline support, not megadose
Omega-3 (ALA precursor)	Precursor pathway to resolvins E1/E2, protectin D1 (nerve protection), LTB4/PGE2 suppression reducing neutrophil chemotaxis	Low ALA-to-EPA/DHA conversion; marine fish oil more efficient; antiplatelet caution
Zinc	Modulates neutrophil oxidative burst, supports FOXP3+ Tregs, MMP cofactor for vessel repair, renal zinc homeostasis	Balance matters; sufficiency not excess; NET relationship is complex
Iodine	Supports normal thyroid function	Variable content; moderate, consistent intake; thyroid caution

A Sensible Daily Approach (With Your Team's Blessing)

If you and your rheumatologist and nephrologist agree that sea moss is a reasonable addition to your nutrition, consistency and communication matter far more than quantity.

Frequently Asked Questions

Related Guides

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Microscopic polyangiitis is a serious, potentially life-threatening systemic autoimmune vasculitis that requires management by a rheumatologist and nephrologist, often with additional specialists, using immunosuppressive therapy and close monitoring. Sea moss is supplemental nutritional support only and does not replace any medical treatment, monitoring, or emergency care. Consult your qualified healthcare provider before making any changes to your routine, especially if you are immunosuppressed, take anticoagulants or antiplatelet agents, have kidney or thyroid involvement, or are at risk of bleeding.